Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Chaim

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Clinical Genitourinary Cancer|May 26, 2022
MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After ProstatectomyAndreas G Wibmer, Robert A Lefkowitz, Yulia Lakhman, et al.
European Radiology|December 7, 2016
Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture AnalysisYulia Lakhman, Harini Veeraraghavan, Joshua Chaim, et al.
The Journal of Urology|November 18, 2020
Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging FindingsAndreas G Wibmer, Joshua Chaim, Yulia Lakhman, et al.
Clinical Genitourinary Cancer|June 1, 2017
Genomic Characterization of Renal Medullary Carcinoma and Treatment OutcomesMaria I Carlo, Joshua Chaim, Sujata Patil, et al.
Cancer Medicine|December 31, 2020
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tractMichal Sarfaty, Karissa Whiting, Min Yuen Teo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2022
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint BlockadeYasser Ged, Alejandro Sanchez, Sujata Patil, et al.
Cancer|September 25, 2020
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trialDarren R Feldman, Yasser Ged, Chung-Han Lee, et al.
European Urology Oncology|November 9, 2023
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney CancerRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
European Urology Oncology|March 30, 2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell CarcinomaRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2018
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial CancersMin Yuen Teo, Kenneth Seier, Irina Ostrovnaya, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Clinical Genitourinary Cancer|May 26, 2022
MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After ProstatectomyAndreas G Wibmer, Robert A Lefkowitz, Yulia Lakhman, et al.
European Radiology|December 7, 2016
Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture AnalysisYulia Lakhman, Harini Veeraraghavan, Joshua Chaim, et al.
The Journal of Urology|November 18, 2020
Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging FindingsAndreas G Wibmer, Joshua Chaim, Yulia Lakhman, et al.
Clinical Genitourinary Cancer|June 1, 2017
Genomic Characterization of Renal Medullary Carcinoma and Treatment OutcomesMaria I Carlo, Joshua Chaim, Sujata Patil, et al.
Cancer Medicine|December 31, 2020
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tractMichal Sarfaty, Karissa Whiting, Min Yuen Teo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2022
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint BlockadeYasser Ged, Alejandro Sanchez, Sujata Patil, et al.
Cancer|September 25, 2020
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trialDarren R Feldman, Yasser Ged, Chung-Han Lee, et al.
European Urology Oncology|November 9, 2023
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney CancerRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
European Urology Oncology|March 30, 2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell CarcinomaRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2018
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial CancersMin Yuen Teo, Kenneth Seier, Irina Ostrovnaya, et al.
Pageof 3